Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose ADME and pharmacokinetic study of [14C]branaplam in healthy male participants
NL-OMON50950Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of branaplam in spinal muscular atrophy (SMA) and Huntington disease (HD), sponsored by Novartis. Primary endpoints: Plasma pharmacokinetics of branaplam and UFB112, Pharmacokinetics of total radiolabeled components in blood and plasma and 1 more. Started Feb 2021; status: active, not recruiting.
02
Drugs
branaplam
03
Conditions
spinal muscular atrophy (SMA)Huntington disease (HD)
Beyond the preview
Go deeper on NL-OMON50950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50950.